Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months. Researchers at Thomas Jefferson University have been working on a cancer vaccine that would extend that survival by activating the patient's immune system to fight the brain tumor. A study published online November 13th in the journal iCancer Immunology, Immunotherapy/i drilled down to the cellular and molecular ...Friday 14 November 2014
Novel Cancer Vaccine Approach to Treat Brain Tumors
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months. Researchers at Thomas Jefferson University have been working on a cancer vaccine that would extend that survival by activating the patient's immune system to fight the brain tumor. A study published online November 13th in the journal iCancer Immunology, Immunotherapy/i drilled down to the cellular and molecular ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment